Statement Of Cash Flows [Abstract]

ABIONYX Pharma - Filing #2813091

Concept 2022-01-01 to
2022-12-31
2021-01-01 to
2021-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Adjustments for interest expense
10,000 EUR
1,000 EUR
Cash flows from (used in) operations before changes in working capital
3 456 EUR
4 948 EUR
Increase (decrease) in working capital
97,000 EUR
1 744 EUR
Adjustments for amortisation expense
135,000 EUR
119,000 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.